keyword
MENU ▼
Read by QxMD icon Read
search

NVAF

keyword
https://www.readbyqxmd.com/read/29445431/outcome-recurrence-and-mortality-after-non-valvular-atrial-fibrillation-stroke-long-term-follow-up-study
#1
Antonio Arauz, Francisco Ruiz-Navarro, Miguel A Barboza, Angelica Ruiz, Jonathan Colin, Marisela Reyes, Humberto Silos, Carlos Cantu-Brito, Luis Murillo-Bonilla, Fernando Barinagarrementeria
Objective: Non-valvular atrial fibrillation (NVAF) is a major risk factor for ischemic stroke (IS) and a powerful predictor of mortality. This study investigates early and long-term outcome among patients with IS secondary to NVAF and identify the main factors associated with poor outcome, recurrence, and death. Methods: We analyzed the data from our consecutive NVAF acute IS database, over a period of 23 years. The endpoints were bad outcome (Modified Rankin Score ≥3), recurrence, and mortality at discharge, after 6 months, 12 months, and final follow-up...
December 2017: Journal of Vascular and Interventional Neurology
https://www.readbyqxmd.com/read/29434525/detecting-clinically-relevant-rivaroxaban-or-dabigatran-levels-by-routine-coagulation-tests-or-thromboelastography-in-a-cohort-of-patients-with-atrial-fibrillation
#2
Yvonne M C Henskens, Anouk J W Gulpen, René van Oerle, Rick Wetzels, Paul Verhezen, Henri Spronk, Simon Schalla, Harry J Crijns, Hugo Ten Cate, Arina Ten Cate-Hoek
Background: Traditional coagulation tests are included in emergency guidelines for management of patients on direct oral anticoagulants (DOACs) who experience acute bleeding or require surgery. We determined the ability of traditional coagulation tests and fast whole blood thromboelastography (ROTEM®) to screen for anticoagulation activity of dabigatran and rivaroxaban as low as 30 ng/mL. Methods: One hundred eighty-four citrated blood samples (75 dabigatran, 109 rivaroxaban) were collected from patients with non-valvular atrial fibrillation (NVAF), to perform screening tests from different manufacturers, (diluted, D) PT, aPTT, TT and ROTEM®...
2018: Thrombosis Journal
https://www.readbyqxmd.com/read/29429636/the-expand-study-efficacy-and-safety-of-rivaroxaban-in-japanese-patients-with-non-valvular-atrial-fibrillation
#3
Hiroaki Shimokawa, Takeshi Yamashita, Shinichiro Uchiyama, Takanari Kitazono, Wataru Shimizu, Takanori Ikeda, Masahiro Kamouchi, Koichi Kaikita, Koji Fukuda, Hideki Origasa, Ichiro Sakuma, Keijiro Saku, Yasuo Okumura, Yuichiro Nakamura, Hideo Morimoto, Naoki Matsumoto, Akihito Tsuchida, Junya Ako, Nobuyoshi Sugishita, Shogo Shimizu, Hirotsugu Atarashi, Hiroshi Inoue
AIMS: The EXPAND study examined the real-world efficacy and safety of rivaroxaban for the prevention of stroke and systemic embolism (SE) in Japanese patients with non-valvular atrial fibrillation (NVAF). METHODS AND RESULTS: This multicenter, prospective, non-interventional, observational, cohort study was conducted at 684 medical centers in Japan. A total of 7141 NVAF patients ≥20 years of age (mean, 71.6 ± 9.4 years) who were being or about to be treated with rivaroxaban (10 mg/day, 43...
February 3, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29423910/kidney-function-monitoring-and-non-vitamin-k-oral-anticoagulant-dosage-in-atrial-fibrillation
#4
Jose Manuel Andreu Cayuelas, Cesar Caro Martínez, Pedro Jose Flores Blanco, Gines Elvira Ruiz, Helena Albendin Iglesias, Juan Jose Cerezo Manchado, Jose Luis Bailen Lorenzo, James Louis Januzzi, Arcadio García Alberola, Sergio Manzano-Fernández
BACKGROUND: Clinical practice guidelines recommend regular kidney function monitoring in atrial fibrillation patients on non-vitamin K oral anticoagulants (NOAC), however information regarding compliance with these recommendations in daily life conditions is scarce. We sought to determine the compliance with kidney function monitoring recommendations in nonvalvular atrial fibrillation (NVAF) patients starting NOAC and its implication on the appropriateness of NOAC dosage. MATERIAL AND METHODS: Retrospective analysis of a multicentre registry including consecutive NVAF patients who started NOAC (n = 692)...
February 9, 2018: European Journal of Clinical Investigation
https://www.readbyqxmd.com/read/29398909/a-survey-of-reasons-for-continuing-warfarin-therapy-in-the-era-of-direct-oral-anticoagulants-in-japanese-patients-with-atrial-fibrillation-the-select-study
#5
Takanori Ikeda, Masahiro Yasaka, Makoto Kida, Miki Imura
Purpose: Although warfarin has historically been the standard of care for preventing ischemic stroke in patients with nonvalvular atrial fibrillation (NVAF), the use of direct oral anticoagulants (DOACs) is rapidly increasing. In this study, we examined the demographic and clinical characteristics of patients continuing warfarin therapy and investigated reasons for warfarin continuation. Patients and methods: Each study site consecutively registered 10 patients with NVAF who had been taking warfarin for at least 12 months...
2018: Patient Preference and Adherence
https://www.readbyqxmd.com/read/29391782/comparison-of-claims-vs-patient-reported-adherence-measures-and-associated-outcomes-among-patients-with-nonvalvular-atrial-fibrillation-using-oral-anticoagulant-therapy
#6
Judith J Stephenson, Mayura U Shinde, Winghan Jacqueline Kwong, An-Chen Fu, Hiangkiat Tan, William S Weintraub
Objective: To compare oral anticoagulant (OAC) adherence among patients with nonvalvular atrial fibrillation (NVAF) using patient-reported and claims-based measures, and to evaluate the effect of OAC adherence on health care costs and patient satisfaction with OAC therapy. Methods: This was a hybrid US observational study consisting of a longitudinal cohort survey followed by linkage and analysis of respondents' administrative claims data. Patients with NVAF receiving warfarin, dabigatran, rivaroxaban, or apixaban completed an initial survey and follow-up surveys at 4, 8, and 12 months...
2018: Patient Preference and Adherence
https://www.readbyqxmd.com/read/29387335/contemporary-utilization-of-antithrombotic-therapy-for-stroke-prevention-in-patients-with-atrial-fibrillation-an-audit-in-an-australian-hospital-setting
#7
Ekta Yogeshkumar Pandya, Elizabeth Anderson, Clara Chow, Yishen Wang, Beata Bajorek
Background: To document antithrombotic utilization in patients with nonvalvular atrial fibrillation (NVAF), particularly, recently approved NOACs (nonvitamin K antagonist oral anticoagulants) and warfarin; and identify factors predicting the use of NOACs versus warfarin. Methods: A retrospective audit was conducted in an Australian hospital. Data pertaining to inpatients diagnosed with atrial fibrillation (AF) admitted between January and December 2014 were extracted...
February 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29384410/strategies-for-improving-dabigatran-adherence-for-stroke-prevention-in-patients-with-non-valvular-atrial-fibrillation-education-and-drug-intake-reminders-facilita-study
#8
Emilio Márquez-Contreras, Nieves Martell-Claros, Sara Márquez-Rivero, Enrique Hermida-Campa, Carmen Gracia-Diez, Eugenio Sanchez-López, Vicente Gil-Guillén
OBJECTIVE: To assess the efficacy of a mixed intervention, educational and reminder calendar of the intake, as a strategy to improve therapeutic adherence with dabigatran in patients with non-valvular atrial fibrillation (NVAF). METHODS: Prospective, longitudinal, multicenter study, carried out in 110 specialized healthcare centers in Spain. 726 patients treated with dabigatran prescribed for stroke prevention were included. A cluster randomization was performed based on two groups: 1) Control Group (CG) as usual clinical practice and Intervention Group (IG) with a mixed strategy: a) Healthcare education and b) Use of a reminder calendar for taking the anticoagulant medication...
January 31, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29382672/time-in-therapeutic-range-and-stability-over-time-for-warfarin-users-in-clinical-practice-a-retrospective-cohort-study-using-linked-routinely-collected-health-data-in-alberta-canada
#9
Finlay A McAlister, Natasha Wiebe, Brenda R Hemmelgarn
OBJECTIVES: Whether warfarin-treated patients with non-valvular atrial fibrillation (NVAF) who exhibit good control will experience deterioration in control over time is uncertain. We designed this study to examine the time in therapeutic range (TTR) in a population-based cohort of patients with NVAF recently initiated on warfarin. DESIGN: Retrospective cohort study using routinely collected health data from 2008 to 2015. SETTING: The Canadian province of Alberta...
January 29, 2018: BMJ Open
https://www.readbyqxmd.com/read/29377394/platelet-predominate-gene-expression-and-reticulated-platelets-in-non-valvular-atrial-fibrillation-effect-of-pulmonary-veins-isolation
#10
Waldemar E Wysokinski, Alfonso Tafur, Yanhong Wu, Naser Ammash, Samuel J Asirvatham, Izabela Gosk-Bierska, Diane E Grill, Joshua P Slusser, Jozef Mruk, Robert D McBane
INTRODUCTION: Reticulated platelet (RP) content is increased in non-valvular atrial fibrillation (NVAF). The purpose of this study was to determine if platelet content, morphology and RP proportion are modulated by platelet genes. METHODS AND RESULTS: Expression of 6 platelet-predominate genes impacting platelet formation and release, platelet count and RP content were assessed in NVAF patients before and 3-4 months after pulmonary veins isolation (PVI) and compared to normal sinus rhythm (NSR) controls...
January 29, 2018: Journal of Cardiovascular Electrophysiology
https://www.readbyqxmd.com/read/29371284/comparative-effectiveness-of-novel-oral-anticoagulants-in-uk-patients-with-non-valvular-atrial-fibrillation-and-chronic-kidney-disease-a-matched-cohort-study
#11
Simone Y Loo, Janie Coulombe, Sophie Dell'Aniello, James M Brophy, Samy Suissa, Christel Renoux
OBJECTIVES: To evaluate the effectiveness and safety of novel oral anticoagulants (NOACs) compared with vitamin K antagonists (VKAs) among patients with non-valvular atrial fibrillation (NVAF), particularly those with chronic kidney disease (CKD). DESIGN: Population-based matched cohort study. SETTING: Over 670 primary care practices in the UK, contributing to the Clinical Practice Research Datalink. PARTICIPANTS: Up to 6818 adult patients newly treated with NOACs between 2011 and 2016, matched 1:1 to new users of VKAs on age, sex and high-dimensional propensity score...
January 24, 2018: BMJ Open
https://www.readbyqxmd.com/read/29363999/all-cause-stroke-systemic-embolism-and-major-bleeding-related-health-care-costs-among-elderly-patients-with-nonvalvular-atrial-fibrillation-treated-with-oral-anticoagulants
#12
Steve Deitelzweig, Xuemei Luo, Kiran Gupta, Jeffrey Trocio, Jack Mardekian, Tammy Curtice, Patrick Hlavacek, Melissa Lingohr-Smith, Brandy Menges, Jay Lin
In this study, all-cause, stroke/systemic embolism (SE)-related, and major bleeding (MB)-related health-care costs among elderly patients with nonvalvular atrial fibrillation (NVAF) initiating treatment with different oral anticoagulants (OACs) were compared. Patients ≥65 years of age initiating OACs, including apixaban, rivaroxaban, dabigatran, and warfarin, were identified from the Humana Research Database between January 1, 2013, and September 30, 2015. Propensity score matching was used to separately match the different OAC cohorts with the apixaban cohort...
January 1, 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/29363835/growth-differentiation-factor-15-is-associated-with-left-atrial-left-atrial-appendage-thrombus-in-patients-with-nonvalvular-atrial-fibrillation
#13
Xiao Feng Hu, Rui Zhan, Shanhu Xu, Junjun Wang, Jiong Wu, Xiaoli Liu, Yaguo Li, Linhui Chen
BACKGROUND: There is evidence suggesting that growth differentiation factor 15 (GDF-15) appears to be associated with stroke in patients with atrial fibrillation (AF). AF-related thromboembolic stroke is predominantly attributed to the thrombus from the left atrium (LA) or left atrial appendage (LAA). HYPOTHESIS: GDF-15 is related to LA/LAA thrombus in nonvalvular AF (NVAF) patients. METHODS: A total of 894 patients with NVAF without anticoagulation therapy were included in this study...
January 24, 2018: Clinical Cardiology
https://www.readbyqxmd.com/read/29360144/agreement-between-coding-schemas-used-to-identify-bleeding-related-hospitalizations-in-claims-analyses-of-nonvalvular-atrial-fibrillation-patients
#14
Craig I Coleman, Tatsiana Vaitsiakhovich, Elaine Nguyen, Erin R Weeda, Nitesh A Sood, Thomas J Bunz, Bernhard Schaefer, Anna-Katharina Meinecke, Daniel Eriksson
BACKGROUND: Schemas to identify bleeding-related hospitalizations in claims data differ in billing codes used and coding positions allowed. We assessed agreement across bleeding-related hospitalization coding schemas for claims analyses of nonvalvular atrial fibrillation (NVAF) patients on oral anticoagulation (OAC). HYPOTHESIS: We hypothesized that prior coding schemas used to identify bleeding-related hospitalizations in claim database studies would provide varying levels of agreement in incidence rates...
January 23, 2018: Clinical Cardiology
https://www.readbyqxmd.com/read/29350390/dual-antiplatelet-therapy-is-safe-and-efficient-after-left-atrial-appendage-closure
#15
Jakub Maksym, Tomasz Mazurek, Janusz Kochman, Marek Grygier, Agnieszka Kapłon-Cieślicka, Michał Marchel, Piotr Lodziński, Radosław Piątkowski, Radosław Wilimski, Paweł Czub, Anna Fojt, Natalia Karolczak, Piotr Hendzel, Grzegorz Opolski
BACKGROUND: Despite of PROTECT AF trial results many patients undergoing left atrial appendage closure (LAAC) have unconditional contraindications to warfarin. AIM: We sought to investigate whether double antiplatelet therapy (DAPT) is safe in patients after LAAC. METHODS: 44 (22 males, mean age 74±7.8) consecutive patients with non-valvular atrial fibrillation (NVAF) underwent LAAC procedure using Watchman device followed by DAPT (75 mg Aspirin and 75 mg Clopidogrel)...
January 19, 2018: Kardiologia Polska
https://www.readbyqxmd.com/read/29349803/assessment-of-mitral-annulus-and-mitral-leaflet-in-nonvalvular-atrial-fibrillation-patients-with-various-degrees-of-mitral-regurgitation-real-time-3d-transesophageal-echocardiography
#16
Yongjuan Luo, Yanbo Zhu, Xin Guan, Yunjia Lin
AIM: To study the changes of mitral valve (MV) in patients with nonvalvular atrial fibrillation (NVAF)-related mitral regurgitation (MR) and the relationship between MV parameters and the enlarged left atrium (LA). MATERIALS AND METHODS: A total of 43 patients with NVAF were divided into two groups: (1) the MR1 group with mild MR and (2) the MR2 group with moderate-to-severe MR. Real time 3D transesophageal echocardiography (TEE) was performed to detect the structure of MV...
January 19, 2018: Echocardiography
https://www.readbyqxmd.com/read/29339167/comparison-of-anticoagulant-therapy-for-atrial-fibrillation-novel-oral-anticoagulants-versus-vitamin-k-antagonists
#17
REVIEW
Sean T Chen, Manesh R Patel
In patients with non-valvular atrial fibrillation (NVAF), oral anticoagulation is important for prevention of stroke and systemic embolism (SE). While Vitamin K antagonists (VKAs) have historically been the standard of care, these medications are limited by numerous food and drug interactions with onerous requirements for frequent monitoring and dose adjustments. Over the past decade, several novel oral anticoagulants (NOACs) have been developed to directly inhibit factor IIa/thrombin (dabigatran) or activated factor X (apixaban, rivaroxaban, edoxaban)...
January 12, 2018: Progress in Cardiovascular Diseases
https://www.readbyqxmd.com/read/29304563/the-anticoagulant-effect-of-therapeutic-levels-of-dabigatran-in-atrial-fibrillation-evaluated-by-thrombelastography-teg%C3%A2-hemoclot-thrombin-inhibitor-hti-assay-and-ecarin-clotting-time-ect
#18
Sacha Solbeck, Annette Schophuus Jensen, Christian Maschmann, Jakob Stensballe, Sisse Rye Ostrowski, Pär I Johansson
Monitoring the effect of dabigatran (Pradaxa®) is challenging. The aim of this study was to evaluate if thrombelastography reaction time (TEG® R) could detect the anticoagulant effect of dabigatran showing a correlation between TEG® R, Hemoclot Thrombin Inhibitor (HTI) assay and Ecarin Clotting Time (ECT) in patients with non-valvular atrial fibrillation (NVAF). Blood samples from 35 AF patients receiving either 110 mg (n 19) or 150 mg (n 16) dabigatran twice daily were analyzed with TEG®, HTI and ECT 2-3 h after dabigatran intake...
January 5, 2018: Scandinavian Journal of Clinical and Laboratory Investigation
https://www.readbyqxmd.com/read/29290177/health-care-resource-utilization-and-costs-among-newly-diagnosed-and-oral-anticoagulant-naive-nonvalvular-atrial-fibrillation-patients-treated-with-dabigatran-or-warfarin-in-the-united-states
#19
Rahul Jain, An-Chen Fu, Jonathan Lim, Cheng Wang, Jessica Elder, Stephen D Sander, Hiangkiat Tan
BACKGROUND: Warfarin has a long history of use to reduce the risk of stroke in patients with atrial fibrillation (AF), but it requires frequent laboratory monitoring to maintain international normalized ratio levels in the therapeutic range. Dabigatran, a novel oral anticoagulant (OAC), has demonstrated efficacy in reducing the risk of stroke and systemic embolism and does not require laboratory monitoring. OBJECTIVE: To compare health care resource utilization (HCRU) and costs of OAC-naive patients newly diagnosed with nonvalvular atrial fibrillation (NVAF), using dabigatran or warfarin...
January 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29260531/-assessment-of-left-atrial-appendage-size-and-morphology-by-enhanced-cardiac-computed-tomography-in-patients-with-non-valvular-atrial-fibrillation
#20
Zhong-Xiu Chen, Wen-Juan Bai, Hong Tang, Wei Cheng, Li Rao
OBJECTIVE: This study was designed to investigate left atrial appendage (LAA) size and morphology characteristics in patients with non-valvular atrial fibrillation (NVAF) by enhanced cardiac computed tomography (CT) scanning,and to evaluate the predictive value of these parameters for thromboembolic risk. METHODS: A total of 189 NVAF patients were prospectively enrolled during December 2012 to January 2014 in West China Hospital of Sichuan University. Fifty-two atrial tachycardia patients without organ dysfunction were also recruited as controls...
November 2017: Sichuan da Xue Xue Bao. Yi Xue Ban, Journal of Sichuan University. Medical Science Edition
keyword
keyword
83853
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"